4//SEC Filing
aMoon 2 Fund Limited Partnership 4
Accession 0000899243-20-013089
CIK 0001797336other
Filed
May 13, 8:00 PM ET
Accepted
May 14, 4:31 PM ET
Size
12.4 KB
Accession
0000899243-20-013089
Insider Transaction Report
Form 4
aMoon 2 Fund Limited Partnership
10% Owner
Transactions
- Conversion
Common Stock
2020-05-12+369,231→ 1,682,549 total - Conversion
Common Stock
2020-05-12+508,924→ 2,191,473 total - Purchase
Common Stock
2020-05-12$15.00/sh+800,000$12,000,000→ 2,991,473 total - Conversion
Series A Preferred Stock
2020-05-12−738,462→ 0 total→ Common Stock (369,231 underlying) - Conversion
Series B Preferred Stock
2020-05-12−1,017,848→ 0 total→ Common Stock (508,924 underlying)
Footnotes (1)
- [F1]Each share of preferred stock was automatically converted into 0.5 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date.
Documents
Issuer
Ayala Pharmaceuticals, Inc.
CIK 0001797336
Entity typeother
IncorporatedCayman Islands
Related Parties
1- filerCIK 0001744099
Filing Metadata
- Form type
- 4
- Filed
- May 13, 8:00 PM ET
- Accepted
- May 14, 4:31 PM ET
- Size
- 12.4 KB